RTB First they have no approved trials underway
Post# of 153937
(Total Views: 665)
Posted On: 04/26/2020 8:52:27 PM
RTB
First they have no approved trials underway yet, FDA gave approval to proceed with application.
They must first get stem cells from a donor, the cost would be high I would believe and to get mass qty's difficult ?
While under general anesthesia, the donor's bone marrow is harvested directly from the hip bones through a large needle. In a peripheral blood stem cell transplant, or PBST, stem cells are harvested from a donor's blood through a process called apheresis.
Seems this treatment is for severe patients once ARDS has set in.
The Drug used is
RYONCIL™ (remestemcel-L) is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in steroid-refractory acute graft versus host disease by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.
First they have no approved trials underway yet, FDA gave approval to proceed with application.
They must first get stem cells from a donor, the cost would be high I would believe and to get mass qty's difficult ?
While under general anesthesia, the donor's bone marrow is harvested directly from the hip bones through a large needle. In a peripheral blood stem cell transplant, or PBST, stem cells are harvested from a donor's blood through a process called apheresis.
Seems this treatment is for severe patients once ARDS has set in.
The Drug used is
RYONCIL™ (remestemcel-L) is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in steroid-refractory acute graft versus host disease by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.
(6)
(0)